SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lessened its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 45.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 85,900 shares of the company's stock after selling 72,100 shares during the period. Two Sigma Advisers LP owned 0.20% of SI-BONE worth $1,204,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SIBN. R Squared Ltd bought a new position in SI-BONE in the 4th quarter worth approximately $73,000. Legato Capital Management LLC boosted its holdings in SI-BONE by 9.1% during the 4th quarter. Legato Capital Management LLC now owns 62,707 shares of the company's stock valued at $879,000 after acquiring an additional 5,209 shares during the period. Rhumbline Advisers boosted its position in SI-BONE by 3.0% in the 4th quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock valued at $808,000 after buying an additional 1,683 shares during the period. Impax Asset Management Group plc raised its position in SI-BONE by 1.1% during the 4th quarter. Impax Asset Management Group plc now owns 766,761 shares of the company's stock valued at $10,750,000 after purchasing an additional 8,240 shares in the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in shares of SI-BONE in the 4th quarter valued at about $155,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SIBN. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial boosted their price target on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th.

Insider Activity

In other SI-BONE news, SVP Michael A. Pisetsky sold 3,128 shares of the company's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total transaction of $44,229.92. Following the transaction, the senior vice president now directly owns 244,878 shares in the company, valued at $3,462,574.92. This represents a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,311 shares of SI-BONE stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the transaction, the insider now directly owns 284,555 shares of the company's stock, valued at approximately $4,026,453.25. This represents a 1.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,565 shares of company stock valued at $1,669,871. 4.00% of the stock is currently owned by company insiders.

SI-BONE Price Performance

SIBN stock traded down $0.04 during trading on Monday, hitting $18.86. The stock had a trading volume of 417,863 shares, compared to its average volume of 378,049. The stock has a market capitalization of $803.72 million, a P/E ratio of -20.50 and a beta of 0.82. The company's 50-day moving average price is $15.62 and its two-hundred day moving average price is $15.34. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. As a group, research analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.